Compounds and Compositions as Protein Kinase Inhibitors

Array Biopharma Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 8 of these applications claim priority to application 12/870,130, filed Aug 27, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 9,593,099	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 9,593,100	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 9,850,229	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 9,850,230	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 10,005,761	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 10,568,884	Compounds and Compositions as Protein Kinase Inhibitors Novartis International Pharmaceutical Ltd. In force Term ends Aug 27, 2030 · High confidence	Novartis International Pharmaceutical Ltd.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US 10,576,080	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma Inc. In force Term ends Aug 27, 2030 · High confidence	Array Biopharma Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	High confidence
US RE49,556	Compounds And Compositions As Protein Kinase Inhibitors Array BioPharma Inc. In force Term ends Aug 27, 2030 · Low confidence	Array BioPharma Inc.	In force	Term ends Aug 27, 2030	Term ends Aug 27, 2030	Low confidence
US 9,314,464	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. In force Term ends Jul 4, 2031 · High confidence	Array Biopharma, Inc.	In force	Term ends Jul 4, 2031	Term ends Jul 4, 2031	High confidence
US 8,501,758	Compounds and Compositions as Protein Kinase Inhibitors Array Biopharma, Inc. Surrendered on reissue Jun 20, 2023 Surrendered on reissue Jun 20, 2023 · Low confidence	Array Biopharma, Inc.	Surrendered on reissue Jun 20, 2023	Surrendered on reissue Jun 20, 2023	Term ended Jun 20, 2023	Low confidence
2 more patents in this group · Pro

10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 12, including 1 expired.

Upgrade to Pro

8 of these are in force and held by Array Biopharma Inc..

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.